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USA 
1. Introduction 
Cancer is a heterogeneous disease that begins locally before spreading and developing 
extended metastasis. The initial tumor initiation and development is the results of a cells 
dysfunction which occurs when accumulated genetic abnormalities transform a normal cell 
into a tumoral cell with the ability of self-renewal and proliferation. While the exact 
chronology of this evolution remains unknown, two major models of tumor cell initiation 
have been proposed (figure 1) (Wang and Dick, 2005): 
In the stochastic model, each cell contains a low but similar probability to acquire the 
necessary genetic mutations resulting in the capacity of proliferation and survival. During 
the life of the cell, accidentals genetics modifications or mutations may occur and result in 
the acquisition of the self-renewal potential and thus the ability to sustain neoplasic growth. 
Then, throughout clonal evolution, cells are subjected to further genetic variations resulting 
in a heterogeneous tumor. In this model, the relative genetic instability of tumoral cells 
accounts for the cellular heterogeneity.  
In the Stem cell model, each cell has a different probability of acquiring a specific tumoral 
phenotype. As a result, beyond a simple monoclonal expansion of transformed cells, tumors 
are more likely considered as a complex tissue where tumor initiation and growth is driven 
by a minority of tumor cells. This population of initiating cells or cancer stem cells (CSC) is 
functionally distinct and exhibit specific activated pathways compared to the bulk cells. 
CSC’s display specific properties such as the capability of self-renewal, asymmetric cell 
division, and capacity to differentiate. The progeny cells - which composed the bulk part of 
the tumor - undergo specific genetic or epigenetic changes resulting in their limited capacity 
to divide and survive. In this model, these genetic changes are not rules by accidental 
genetic events but more likely driven by specific regulations pathways. While the origin of 
these CSC remains unknown, it is hypothesized that they derive from normal tissue stem 
cells, or from partially differentiated progenitor cells acquiring unlimited self-renewal 
potential. Stem cells seem to be the ideal candidates to support this model because of their 
long life span, which allows for the accumulation of multiple mutations events contrary to 
the differentiated one. 
In hematological malignancies, tumor-initiating cells have been identify and strongly 
supports the stem cells model. In solid tumors, emergent observations argue for this theory 
but still require further investigation and validation. 
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Only CSC cells present a self renewal ability 
completed by ability to asymmetric cell division 
All mutated cells presents a self-renewal 
ability with initial monoclonal expansion 
  
B/ STEM CELLS MODEL : 
Stem cells are the only concern  
by accidental mutations  
A/STOCHASTIC MODEL: 
All cells are potentially concern 
 by accidental mutations  
 
Fig. 1. Two models of tumor initiation 
Using colon cancer as an example, this chapter will provide an overview of the complexity 
of CSC identification and characteristics. Based on the description of different implicated 
pathways, we’ll try to tackle possible clinical applications. 
2. Cancer stem cell: identification 
As suggested above, CSC’s can be differentiated from the bulk part of the tumor either by 
their specific surface markers or by the specific pathways involved. Considering the 
example of hematologic malignancy and the supposed origin of the CSC, the first markers 
used to identify this specific cells subset were common with the normal stem cells of the 
tissue of origin. The CD 133 antigen is for example commonly expressed both by malignant 
stem cells and the stem cells of the tissue of origin. On the contrary the CD20 antigen, highly 
express in colon tissue cells, is not express by the CSC.  
2.1 Colon cancer stem cells: CD133 
The CD133 antigen (Human prominin 1, PROML1) is a 5-transmembrane glycoprotein of 
865 amino acids (120kDa) that is localized to membrane protrusions or microvilli in the 
colon. This antigen has been used as a marker to enrich for human hematopoietic stem cells 
and its expression has been correlated with CSC in solid tumors including prostatic cancer 
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(Richardson et al., 2004), kidney cancer (Florek et al., 2005), non-small cell lung carcinoma 
(Zhang et al., 2007), and ovarian cancer (Ferrandina et al., 2008). 
Using 17 samples of human colonic cancer (6 primary, 10 liver metastases, 1 lung 
metastases), O’Brien et al. conducted serial xenograft implantations through the sub-renal 
capsule of diabetic (NOD)/severe-combined immunodeficient (SCID) mice (O'Brien et al., 
2007). Only the CD133+ cells implanted for xenografts generated tumors. By 
immunohistochemistry (IHC) the CD133 expression ranged from 1.8 to 24% in the colon 
cancer samples and from 0.4 to 2.1% in the normal colon cells. The frequency of CSC in the 
CD133+ cells fraction was estimated to be 1 in 262 cells. 
At the same time, Luccia Ricci-Vitani et al. reported their observation of both in vitro and in 
vivo culture of CD133+ cells sorted by flow cytometry shortly after tissue dissociation of 
colon cancer samples (Ricci-Vitiani et al., 2007). Again, only the CD133+ cells generated 
tumors in their xenograft models. The samples analyzed exhibited a very low frequency of 
CD133+ cells, with only 2.5 ± 1.4 % among a large excess of CD133- cells. In this study, the 
presence of CD133+ cells was barely detectable from normal colon tissues (Ricci-Vitiani et 
al., 2007). Several other reports confirmed the implication of CD133+ cells in tumor initiation 
(Vermeulen et al., 2008, Dalerba et al., 2007). Furthermore, the level of CD133 expression has 
been shown to be correlated between the primary tumor and corresponding metastasis in 
94% of cases (15 patients out of 16) (Horst et al., 2009).  
Thus, the definition and identification of colon CSC remains incomplete. As suggested by 
O’Brien et al, among these CD133+ cells only a few selected cells are expected to be “real 
CSC”(O'Brien et al., 2007).  The heterogeneous cell population in colon cancer is partly 
highlighted by its multiplicity of the genetics combinations disorders found. Hence, it is 
likely that among CSC, several phenotypic profiles may exist, sharing some common 
markers and signaling pathways.  
Several studies have investigated other potential CSC markers. It is important to note, that 
all the presented studies focused on colon CSC identification, actually isolated a “CSC-
containing” subpopulation with different degree of sensitivity and specificity as there is 
probably no ideal single marker for CSCs in any tumor system. 
2.2 Colon cancer stem cells: EpCAM, CD44 and CD166 
The CD44 antigen is a cell surface glycoprotein expressed on lymphocyte, monocyte and 
granulocyte cells which has also been correlated to undifferentiated cells. Dalerba et al. 
explored therefore that alternative profile to identify CSC (Dalerba et al., 2007). They 
examined the expression profile of two markers, CD44 and EpCAM previously described as 
a key to identify CSC in breast cancer (Ponti et al., 2006).  
EpCAM is a glycosylated 40 kDa type I transmembrane glycoprotein and functions as an 
intercellular adhesion molecule modulating cadherin-mediated adhesions and thereby 
adhesion strength. The physiologic expression of EpCAM in an adult’s human tissue is 
restricted to the basolateral cell membrane of glandular, pseudo-stratified and transitional 
epithelia cells. Although the biological role of EpCAM is not fully understood, its 
overexpression has been observed in several cancers’ types, including colon cancer 
(Stoecklein et al., 2006, Todaro et al., 2007, Munz et al., 2009, Gires et al., 2009). The study 
discriminated between two main expressions’ profiles, EpCAMhigh/CD44+ and 
EpCAMlow/CD44-, and measured their detectable in both colon cancer cells and normal 
epithelial colon cells. The frequency of the EpCAMhigh/CD44+cells profile was higher in 
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some cancer cells population than in normal epithelial colon cells (mean frequency of 1.6% 
vs. 5.4%, respectively). The study went on to test the ability of these cell populations to form 
xenografts. While 104 EpCAMlow/CD44- cells graft failed to form a tumor in vivo, as few as 
200 to 500 EpCAMhigh/CD44+ cells consistently generated tumors.  
To specify the characterization of this EpCAMhigh/CD44+ cell population, another set of 
surface markers was tested and included CD133, CD49f, ALDH and CD166 (Dalerba et al., 
2007). Aldehyde dehydrogenase (ALDH) is an enzyme involved in intracellular retinoic acid 
production and has been linked to cellular differentiation during development, playing a 
role in stem cell self-protection (Croker et al., 2009). ALDH enzymatic activity was measured 
in the EpCAMhigh/CD44+ and EpCAMlow/CD44- cells and found to be higher in the 
majority of the EpCAMhigh/CD44+ cells. CD49f, also known as integrin alpha 6, functions in 
cell adhesion and cell-surface mediated signaling.  CD49f expression was measured on the 
tumor cells and correlated with CD44 expression.  The study found CD49f expression on 
tumor cells with higher levels of CD44.  
In these experiments using EpCAMhigh/CD44+ as CSC markers, the expression of CD133 in 
the selected cells appears heterogeneous. Some tumors displayed a homogeneous negative 
or positive expression, while others were composed of a mixture of positive and negative 
CD133 cells. When CD133 was expressed, the CD133+ population includes the CD44+ cells. 
The CD44+ antigen may be therefore more specific to identify the CSC than the CD133+, 
while the results do not always correlate between studies.  
In Dalerba et al. experiments, the CD166 (cluster of differentiation 166), was found to be 
differentially expressed on colon cancer cells but all colon tumors contained a distinct 
fraction of EpCAMhigh/CD44+/CD166+ cells. The study went on to compare the 
tumorigenic potential of the fraction of CD44+/CD166+ and CD44+/CD166- cells and found 
that in serial xenografts, only the CD44+/CD166+ cell population was tumorigenic.  
Haraguchi et al. demonstrated that utilizing both CD133 and CD44 may enhance the 
selection of tumor initiation cells for colon cancer and by treated colon cancer cells with the 
differentiation’s inducer, sodium butyrate (NaBT), there was a decrease in the expression of 
CD133 and CD44 (Haraguchi et al., 2008).  In this study, the expression of CD44 and CD133 
in clinical samples varied from 11.5% to 58.4%  (mean 30%) and from 0.3 % to 82% (mean 
35.5%) respectively, while the frequency of the CD133+/CD44+ cells population ranged 
from 0.2 to 15.73% (mean 7%). As expected, when injected in NOD/SCID mice, the CD44+ 
or CD133+ populations induced tumor formation, whereas the CD44- and CD133- did not. 
Interestingly, only the CD133+/CD44+ subset population was able to initiate tumors 
whereas CD133+/CD44- and CD133-/CD44- could not. The subset of CD133-/CD44+ 
population was too small to evaluate in a xenograft study.  
Based on these observations, Du et al. proposed to discriminate the respective functional 
importance of CD44 and CD133 (Du et al., 2008). In contrast with previous reports, this 
study found that CD44+ cells displayed cluster growth and did not co-localize with CD133+ 
cells within colorectal cancer (CRC). As few as 100 CD44+ cells were able to initiate tumor 
formation in a xenograft model utilizing NUDE mice. Knockdown of CD44+ prevented 
clonal formation and inhibited tumorigenicity in a xenograft model, whereas knockdown of 
CD133+ did not. 
2.3 Colon cancer stem cells: CD24 and other markers 
Within spheroid cultures of primary cancer cells, Vermeulen et al. identified several 
heterogeneous subpopulations expressing stem cells markers such as CD133+, CD24+, 
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CD44+, CD166+, Lgr5 (Vermeulen et al., 2008). Using single-cell sorting of spheroid cells by 
flow cytometry, they established that only 1 out of 20 cells has the ability to induce 
monoclonal culture. Among these cells, those presenting a co-expression of CD133 and 
CD24 were identified as the clonogenic subset, whereas the co-expression of CD133 with 
CD44, CD166, Lgr5 or CD29 did not increase the selection.  
Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) was initially identified 
as an orphan receptor and a Wnt target gene in colon cancer. On intestinal tissues, Lgr5 
expression has been identified to be restricted to the bottom of the crypt and not the villi 
(Takahashi et al.). However, in premalignant lesions, Lgr5+ cells were not restricted to the 
crypt base, but were found also at the surface of the crypt (Becker et al., 2008). While its 
expression has not been precisely related to CSC, it has been recently shown to be 
overexpressed in ovary, liver cancers and colon cancer (Takahashi et al.). 
 
Marker Colon cancer Other solid cancers Function 
CD133 
(O'Brien et al., 2007),  
(Ricci-Vitiani et al., 2007), 
(Vermeulen et al., 2008, 
Dalerba et al., 2007), 
(Haraguchi et al., 2008), 
(Zhu et al., 2009) 
Prostate (Richardson et al., 2004),  
Kidney (Florek et al., 2005) ,  
Non-small lung (Zhang et al., 2007), 
Ovarien (Ferrandina et al., 2008), 
Hepatocarcinoma (Tomuleasa et al.)
transmembrane 
glycoprotein,  
self-renewal 
CD44 
(Dalerba et al., 2007), 
(Haraguchi et al., 2008),  
(Du et al., 2008) 
Breast (Ponti et al., 2006),  
Head and neck (Joshua et al.), 
Glioblastoma (Anido et al.),  
Non-small cell lung (Leung et al.), 
Gallbladder (Shi et al.) 
cell surface 
glycoprotein,  
cell adhesion, 
hyaluronic  
acid receptor 
EpCAM (Ponti et al., 2006) 
Breast (Ponti et al., 2006), 
Esophagus (Stoecklein et al., 2006) 
transmembrane 
glycoprotein, 
intercellular 
adhesion 
molecule 
CD24 (Vermeulen et al., 2008) 
Pancreatic (Rasheed et al.),  
Breast (Huang et al.),  
Gastric (Takaishi et al., 2009) 
cell surface 
glycoprotein  
Cell adhesion 
CD166 (Ponti et al., 2006) Prostate (Rowehl et al., 2008) 
cell surface 
glycoprotein  
Cell adhesion 
ALDH (Huang et al., 2009) 
Lung (Sullivan et al.),  
Sarcoma (Awad et al.) 
Enzyme, cellular 
differentiation 
Lgr5 
(Takeda et al.,  
Takahashi et al.) 
Colon, Rectum, 
G protein-coupled 
receptor,  
Wnt targeted gene 
Abbreviations: EpCAM: Epithelial cell adhesion molecule; ALDH: Aldehyde dehydrogenase;  
Lgr5: Leucine-rich repeat-containing G-protein coupled receptor 5 
Table 1. CSC markers explored according to the cancer type 
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Using the same process, cells expressing ALDH1 were demonstrated to be highly 
tumorigenic compared to the ALDH1- ones. Among them further isolation of cancer cells 
using a second marker like CD133 or CD44 modestly increased the enrichment in tumor-
initiating cells (Huang et al., 2009). 
3. Cancer stem cell, definition 
The CSC are defined by their ability of self-renewal, asymmetric cell division and 
differentiation. In colon cancer, the evidence of existing CSC was first reported in 2007 by 
two groups independently (Ricci-Vitiani et al., 2007, O'Brien et al., 2007). Using a xenograft 
model of colon cancer cells into nude mice, these studies demonstrated that only a small 
subset of tumor cells was able to generate a tumor. Based on previously known stem cells 
markers, they demonstrated that only the tumor cell fraction harboring the CD133 or CD44 
marker was tumorigenic. 
3.1 Tumor initiation (in vivo) 
All tumors are comprised of a heterogeneous population of cancer cells. In xenograft 
experiments, it has been demonstrated that only a minority of the cells from heterogeneous 
cell population retain the ability to generate a tumor.  
Since the early 1900’s, xenografts of colon cancer cells into irradiated hamsters were 
successfully performed (Murphy, 1914). The implantation of human colonic cancer cells into 
diabetic NOD/ SCID mice to induce tumor formation was later routinely used to investigate 
cancer metabolism. Yet, limiting dilutions experiments demonstrated that this tumor 
initiation was dependent on the amount of injected cells (O'Brien et al., 2007, Ricci-Vitiani et 
al., 2007). These studies demonstrate that if 1x105 cells or more were injected, tumor 
formation occurred systematically but below this, the efficiency of these grafts decreased. To 
clarify this decrease in engrafting efficiency, cancer cells were separated in several fractions 
before being injected into NOD/SCID mice at different dilutions of cells. The cells were 
fractioned utilizing the CD133 stem cell marker into CD133+ and CD133- cells. After 
injecting CD133- cells, less than 2% of the mice transplanted with the higher cell dose 
generated a tumor. In contrast, tumors were generated systematically after injection of 1 x 
103 or more CD133+ cells. Moreover, only the CD133+ cells were able to initiate tumor 
growth in secondary and tertiary mice, providing the first evidence of the existence of a 
small sub-population of cancer initiating cells (O'Brien et al., 2007, Ricci-Vitiani et al., 2007, 
Ieta et al., 2008, Varnat et al., 2009). By extension, this suggests that only this small fraction 
of cancer cells may be responsible for the metastasis development, while it has never been 
demonstrated. 
3.2 Self-renewal (in vitro) 
Cancer cells are defined by their ability to divide and renew endlessly. This observation has 
been confirmed by the in vitro experiments, yet this tumoral property is limited to a specific 
subset of cells among a tumor.  
Studies have shown that colonic tumoral cells can be cultivated in serum-free medium 
containing epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF-2). In this 
medium, the culturing of four weeks of CD133+ cells resulted in colon spheres formed by 
aggregates of exponentially growing undifferentiated cells whereas CD133- cells invariably 
died. This CD133+ tumor spheres maintained their tumorigenic potential when injected into 
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SCID mice and generated rapidly growing tumors. Tumor xenografts derived from colon 
sphere can be their self-maintained in culture for at least twelve months (Ricci-Vitiani et al., 
2007, Todaro et al., 2007). 
By contrast, in serum-containing medium without EGF and FGF-2, CD133- cells 
demonstrated growth for 2 weeks before declining in number. In this medium, it was 
observed that CD133+ cells gradually migrated and began to differentiate.  
In these experiments, the CD133- population cells exhibited only limited self-renewal ability, 
resulting in cell death when cultured in vitro. Yet this population of cells is still classified as 
tumoral due to their displaying features of gastro-intestinal cancer like carcinoembryonic 
antigen (CEA) expression, and adenomatous polyposis coli (APC) or p53 mutation. These 
observations clearly demonstrated in vitro the differential property of tumoral cells to 
survive in culture conditions.  
3.3 Differentiation ability 
3.3.1 In vitro 
The differentiation’s ability of the CSC accounts for the tumor heterogeneity. In serum-
containing medium without EGF and FGF, after one day of culture, CD133+ cells gradually 
migrate and differentiate into large and adherent cells. During their differentiation, these 
cells acquired CK20 expression and a similar morphology to the original tumor. In the 
meantime, they lost their ability to transfer tumor in SCID mice (Ricci-Vitiani et al., 2007).  
This differentiation is not correlated to accidental mutations as the experiments with CD133 
or CD44 cells consistently reproduced the same behavior in vitro. This asymmetric division 
is more likely the result of highly specific cells controls supporting the stem cells model 
compared to the stochastic model.   
3.3.2 In vivo 
The relative proportion of “CSC-cells” profile varied among xenograft lines but is conserved 
within each line of successive in vivo transplantation in immunodeficient mice. CD133+ 
tumor cells isolated from xenograft of colon cancer samples demonstrated a similar ability to 
generate tumors that contained the same range of CD133+ and CD133- cells compared to the 
original tumor (O'Brien et al., 2007, Todaro et al., 2007, Ricci-Vitiani et al., 2007, Vermeulen 
et al., 2008). Similarly, tumor generated from EpCAM high/CD44+ cells (other putative CSC 
markers) reproduced the same phenotypic heterogeneity as their parents and contained 
both and in same proportion EpCAMhigh/CD44+ and EpCAMlow/CD44- populations 
(Vermeulen et al., 2008). 
During the differentiation process, the cells gradually lose their stem cell markers. These 
markers allow us to precisely discriminate the subset of CSC among a large excess of other 
cells, including bulk tumor part cells and circulating cells. It is critical to note that this 
differentiation process always reproduces the heterogeneity of the parental tumor. A tumor 
must be therefore considered as a complex hierarchically organized tissue involving specific 
pathways and regulatory mechanism.  
3.4 Treatment resistance 
Because the CSC are the only tumor initiating cells, it is suggested that the cancer treatment 
will not be successful unless this population of cells can be completely eradicated. Yet, there 
is growing evidence that CSCs are naturally resistant to both radiation, and the majority of 
chemotherapies (Pajonk et al.). 
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The CSC intrinsic radio-resistance, has been demonstrated in different solids tumors such as 
breast cancer (Phillips et al., 2006), medulloblastoma (Blazek et al., 2007), or glioma (Chang et 
al., 2009) with an enrichment of the CSC fraction post tumor treatment. In colon cancer, the 
tumor exposition to chemotherapy and radiotherapy has been shown to increases the CD133+ 
cells fraction proportionally to the time and intensity of the application (Saigusa et al.).  
The relative chemoresistance of the CSC compared to the stemness cells is now becoming a 
part of the CSC definition (Song et al., 2009). The CSC chemoresistance resulted from the 
conjunction of two phenomenon. First, several pathways are differentially expressed by the 
CSC compared to the bulk counterpart. Some of these have been implicated in chemo-
resistance and will be further described.  Second, in analogy with the adult stem cells, the 
CSC are postulated to remain quiescent in their niche and therefore responsible for late 
recurrent disease. As most of the chemotherapeutic agents act through disruption of the 
mitotic phase of cancer cell-cycle, quiescent CSC are relatively protected against these 
cytotoxic agents. This hypothesis has been confirmed by several experiments. In xenograft 
model, the CSC from colon cancer labeled with dye injected to nude mice demonstrated to 
remain in a state of quiescence. This quiescence was shown to be reversible when mice were 
exposed to chemotherapy (paclitaxel) (Kusumbe and Bapat, 2009). 
Consequently to this chemo-resistance, it has been shown that tumor submitted to 
chemotherapy demonstrated enrichment in the stem cell fraction. In hepatocarcinoma, CSC 
were injected into nude mice treated with different doses of chemotherapy 
(cyclophosphamide). Cells sorted from these generated tumors presented in vitro a self-
renewal potential increasing with the increasing dose of chemotherapy. Similarly, in a 
secondary xenograft, the ability of these enriched cells to produce xenograft in mice was also 
dependent on the chemotherapy dose (Tan et al., 2009). In breast cancer, doxorubicin-
selected cells demonstrated a higher tumorigenic potential in Matrigel when compared to 
the parental cells (Calcagno et al.).  
4. CSC pathway and possible applications 
Considering the CSC theory, effective anticancer drugs should target not only the tumor 
bulk but also specifically the tumor initiating cells. As CSC are considered to be drug-
resistant compared to their bulk counterpart due to their elevated expression of the family 
of ATP-binding cassette (ABC) transporters and their low proliferation rate. This drug 
resistance is thought to be responsible for tumor recurrences, as these cells persist after 
treatment and compose the “minimal residual disease”. Characterizations of specific 
signaling pathway exclusively used by CSC, and not by the tumor bulks cells or by the 
normal colon cells or the normal colon stem cells is indeed a new challenging area for 
research. First it enriches the CSC definition by physiological understanding, and second it 
allows the development of new specific CSC targeted therapy. Similarly to normal stem 
cells, CSC’s rely on pathways that govern development, cell-renewal and apoptosis. It is 
excluded to realize a thorough review of the explored pathway as the variety of explored 
pathways is important and as most of these publications consisted in initial observations 
which need to be further examinated. This chapter will thus focus on several of the major 
implicated pathways in CSC pathology.   
4.1 Wnt/β-catenin signaling pathway 
The Wnt signaling pathway plays a critical role in cellular processes including proliferation, 
differentiation, mobility, survival and apoptosis (Takahashi-Yanaga and Kahn). The 
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relevance of Wnt signaling is underlined by the frequency of its aberrant activation in a 
large diversity of malignancy. The regulation of this pathway is provided by the 
cytoplasmic concentration of ǃ-catenin. In the cytoplasm, ǃ-catenin concentration is 
maintained at a low level by the adenomatous polyposis coli (APC) complex. This complex 
of axin, APC and glycogen synthase kinase-3ǃ (GSK- 3ǃ) phosphorylates ǃ-catenin which 
results in its degradation mediated by the proteasome. Wnt binds to a transmembrane 
receptor complex comprised of Frizzled (Fz)/ low-density lipoprotein receptor-related 
protein (LRP) and disheveled (Dvl) leads to its phosphorylation thereby inhibiting GSK-3 ǃ 
(so the APC complex) and unphosphorylated ǃ-catenin then localizes to the nucleus. In the 
nucleus, ǃ-catenin functions in conjunction with a transcriptional complex composed of TCF 
(T-cell transcription factor), LEF (lymphoid enhancer-binding factor), and co activators 
including CBP, cAMP, and p300 to activate the expression of “Wnt-targeted genes”. E-
cadherin functions as a sequestering protein of ǃ-catenin on the cell membrane (Wang et al., 
2004). In spheroidal culture, CSC’s (defined as CD133+/CD166+cells) showed heterogeneity 
in the Wnt signaling network accompanied by heterogeneity in ǃ-catenine localization, 
although these cells all carried an APC mutation (Vermeulen et al.). On microarray analysis 
of these CSC CD133+/CD166+, two capital fractions were described. The TOP-GFPhigh cells 
fraction (reporter that provides the evidence of Wnt signaling activation) demonstrated up-
regulation of the expression of stem-cell-associated genes like LGR5, and revealed a higher 
clonogenic potential in vitro. In vivo, this fraction demonstrated the ability to induce tumors 
in immunodeficient mice. In contrast, the TOP-GFPlow cells fraction expressed epithelial 
differentiation associated gene like mucin 2 (MUC2), cytokeratin 20 (CK20), keratin 20 
(KRT20) and fatty acid binding protein 2 (FABP2) (Vermeulen et al., Sikandar et al.). 
As in spheroidal culture, each cell lines remains independent and therefore it can be 
concluded that the regulation of the Wnt pathway is insured at least in part by the cells 
intrinsic features.   
As expected, the TOP-GFPhigh fraction cells, when cultivated in serum-containing medium 
progressively acquire differentiation marks and lost CSC markers. Interestingly, when co-
cultured with myofibroblast cell lines (MCFM), their morphological and molecular 
differentiation was prevented and their clonogenicity highly improved (50 fold). A cytokine 
antibody array revealed that the hepatocyte growth factor (HGF) was one of the most 
abundant factors present in MFCM. This HGF modulated nuclear ǃ-catenin activity though 
c-MET. Exposure of TOP-GFPlow cells to MCFM induced their re-expression of CSC markers 
and restored their clonogenic potential. Regarding these results, CSC are not only 
independent cells clones driving the tumor growth but their activity is highly related to their 
microenvironment. 
This cooperation between the CSC and the corresponding stromal cells is crucial and 
established a link between the CSC and previous reports concerning the tumor progression. 
These results has been confirmed in several solid tumors models including the pancreatic 
cancer (Moriyama et al.). 
Another study, focused on the respective correlation between CD133+ cells and Wnt 
pathway. Mice model were generated with a knock down for one or two of the CD133 
alleles were created (Zhu et al., 2009). Surprisingly, mice completely knockout for CD133 
were viable and demonstrated normal development. The tissue expression of CD133 in 
heterozygote embryos (CD133+/CD133-) was initially found to be restricted to the central 
nervous system, kidney, intestine and skeletal system. As the mouse developed, the CD133 
expression expanded to other organs either by differentiated or undifferentiated cells. In the 
small bowel, the CD133+ expression was relatively restricted in the crypt base and 
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overlapped with that of LGR5. The activation of the endogenous Wnt pathway in 
heterozygous CD133+/CD133- mice resulted initially in a complete disruption of the crypt 
architecture related to a major proliferation of CD133+ cells at the base of the crypt. Lineage-
tracing demonstrated that the entire intestine mucosa was replaced by the progeny of these 
cells resulting in high-grade focal neoplasic formation.  
Wnt pathways play an important role in cells maintenance of pluripotency, however it is 
also involved in differentiation of embryonic cells. Recently it has been demonstrated by 
Kahn et al. that in the Wnt pathway, the co-activateurs CBP and p300 are the mediator of 
this balance pluripotency/differentiation (Ma et al., 2005). Indeed, CBP/ǃ-catenin-mediated 
transcription is involved in undifferentiated stem cells maintenance while CBP/ǃ-catenin-
mediated transcription is involved in cells differentiation. They demonstrated in vitro that 
combined treatment with imatinib mesylate (IM) and ICG-001, which is specific inhibitor of 
binding to the N-terminus of CBP, significantly inhibited colony formation of chronic 
myeloid leukemia progenitors isolated from two patients resistant to IM (Kim et al.). The 
Wnt pathway is one of the most important pathways being evaluated in stem cell research 
and is therefore a target for new cancer therapy development.   
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Fig. 2. Wnt/ǃcatenin signaling pathway 
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4.2 NOTCH signaling pathway 
In mouse models, it has been shown that NOTCH signaling plays an important role in the 
intestinal tumor initiation. In colon CSC, the NOTCH signaling components are highly 
expressed compared to the usual colonic cell lines. This expression plays a critical role in 
CSC self-renewal. Knockdown of the NOTCH pathway in APC mutant cells resulted in cells 
differentiation into post-mitotic goblet cells. In plate culture, colon CSC treated with 
NOTCH inhibitors could no longer form adenocarcinoma glands but only disorganized cells 
cluster without self-renewal capacity (Sikandar et al.).  
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Fig. 3. Notch signaling pathway 
4.3 Akt and MAPK signaling pathway 
An activation of the epidermal growth factor receptor (EGFR) turns on at least five different 
signaling pathways: the mitogen-activated protein kinase (MAPK), phospholipase C, 
phosphatidylinositol 3-kinase (PI3K)/AKT, signal transducer and activator of transcription 
(STAT), and SRC/FAK pathways. These pathways form an intersecting biochemical 
network that, when mutated, drives cell growth in a manner unrestricted by environmental 
cues (Laurent-Puig et al., 2009).  
To assess the critical role of these pathways in CSC, a cDNA GeneChip analysis was 
performed in cells marked CD133+ or CD133- extracted from samples of metastatic colon 
cancer (Wang et al., 2006). In total, 321 genes were up-regulated and 65 down-regulated in 
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CD133+ cells compared with the CD133- cells. The gene expression (examined by real-time 
PCR) confirmed that the changes preferentially concerned PI3K/AKT, NOTCH, Janus 
kinase/signal transducer and activator of transcription STAT, MAPK and transforming 
growth factor (TGF)-ǃ pathways. More precisely, AKT was significantly activated and 
Erk1/2 up-regulated in CD133+cells. When cultured in soft-agarose in the presence of the 
AKT inhibitor II (SH-5), AKT inhibitor IV or MAPK inhibitor (U0126), there was a decrease 
in the ability of the CD133+ cells to form colonies formation by 3 to 11 fold. In gene 
knockdown experiment, cells transduced with AKT and Erk shRNA also demonstrated a 
reduction in their ability to form colonies. 
4.3.1 AKT 
Previous studies have suggested the implication of the AKT pathway in colorectal CSC. 
Thymosin-ǃ-4 (Tǃ4) is an ubiquitous G-actin sequestering molecule and has been shown to 
be involved in a great number of cellular functions such as adhesion, differentiation, 
migration, angiogenesis, apoptosis and metastasis. Aberrant expression of Tǃ4 has been 
reported in CRC and associated with inducing tumoral progression therefore, Ricci -Vitani 
et al. focused on the Tǃ4 expression as a potential critical factor in CSC metabolism (Ricci-
Vitiani et al.). Real-time PCR confirmed by Northern and Western blot analysis showed an 
over-expression of Tǃ4 in CSC (CD133+/CD44+) compared to normal epithelial colon cells. 
Transduced knockdown cells for Tǃ4 resulted in vitro in their reduced tumor growth ability 
(50% lower) and their impairment of migration capacity. These knockdown cells showed a 
decrease of ALDH1 and LGR5 expression (mainly expressed by colon stem cells) whereas 
differentiation genes like CK20 and trefoil factor 1 were up-regulated. In a xenograft model, 
tumor growth ability was decreased. Further analysis reveals that Tǃ4 over-expression was 
responsible for increasing integrin-linked kinase and decreasing PTEN expression resulting 
in AKT pathway activation.  
In other experiment, PI3K inhibition of CD133+/CD24+ CSC cells resulted in their 
“enterocyte-like” differentiation (Vermeulen et al., 2008).  
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Fig. 4. AKT signaling pathway 
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4.3.2 TLR and MAPK 
Toll-like receptors (TLR) are a family of transmembrane receptors that contribute to activate 
the MAPK pathway via the adaptator molecule myeloid differentiation primary-response 
protein 88 (My88). In their study, Grimm et al. gave evidence of a correlation between TLR 
expression and tumor progression (Grimm et al.). Tumoral colon tissues demonstrated a 
higher expression of TLR 7, 8, 9 or 10 when compared to normal colon tissue. The intensity 
of this expression correlated with tumor stage and was higher for the late stage tumor (in 
the UICC classification). The TLR 7 and 8 were shown to be co-expressed with CD133+ in 
tumor cells. 
4.4 CSC and Interleukin-4  
Confirming the CSC drug resistance, Todaro et al (Todaro et al., 2007) analyzed the cell 
viability of primary colon cancer cells following exposure to oxaliplatin and/or 5-
fluorouracil (5-FU). In vitro, the CD133-cells fraction showed a dose-dependent high 
sensitivity to these drugs whereas CD133+ cells were largely resistant, even at higher dose. 
Among the different pathways implicated in drug resistance the interleukin-4 (Il 4) 
mediated signaling has been shown to strongly modulate the death receptors and 
chemotherapy-induced apoptosis. In this study, colon cancer samples showed a high level 
expression of IL4 compared to normal colon specimens. More precisely, the CD133+ cells 
fraction was shown to express both IL4 and IL-4Receptorǂ. A significantly increase in 
overall death was observed in vitro when CD133+ cells treated with either oxaliplatin and or 
5-FU alone or in combination with an IL4-neutrilizing antibody (p<0.001). Anti-IL4 
treatment resulted in a decrease in the protein expression of anti-apoptotic molecules, cFLIP, 
Bcl-xl, and PED. In vivo, nude mice were engrafted with CD133+ cells and treated by an 
intraperitonal injection with IL-4DM (IL-4 Rα antagonist) followed (24 hours later) by 
chemotherapy (oxaliplatin or/and 5-FU). The co-treatment resulted in a marked synergistic 
effect on the tumor growth compare with single agent chemotherapy. 
4.5 CSC and Taxoid-T-1214 
To assess the efficiency of a new-generation taxols, Botchkina et al designed an experimental 
protocol to discriminate the respective effects of Taxoid (SB-T-1214) both on CSC and on the 
tumor bulk (Botchkina et al.). CSC were isolated form three tumor CRC cells lines (DLD-1, 
HCT116 and HT29) according to their CD133high/CD44high phenotypic expression. The 
cytotoxic effect of SB-T-1214 on CSC was studied in two different setting which promoted 
the stemness phenotype. First, the CSC’s were seeded as an adherent monolayer to type I 
collagen in the serum-free medium for 2 days and then incubated with increasing doses of 
SB-T-1214 for 48 hours (100nM to 1μM). The vast majority of cells underwent apoptosis  
(89-96%). The 4-11% of survival cells displayed multiple abnormality including enlarged 
size, multiple nuclei and severe vacuolization.    
Secondly, the experiments were performed in spheroidal cultures. Again, administration of 
of increasing does SB-T-1214 induced apoptosis in greater than 90% of the CRC cells. The 
few surviving cells lost their ability to form secondary spheroids colonies.  
4.6 Aurora Kinase-A  
Aurora-A (STK15/BTAK), is a member of a serine/threonine kinase family, and is involved 
in mitosis entry, control of centrosome maturation, and segregation during mitosis. Aurora-
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A is a key regulator of the p53 pathway, and it’s over expression abrogates the wild-type 
function of p53 such as growth regulation and apoptosis and further confers resistance to 
chemotherapeutic agents. Cammereri et al. explored this pathway regulation in CSC 
isolated from colon cancer specimen (defined CD133+CD29+CK20- cells phenotype) 
(Cammareri et al.). RNA analysis showed that Aurora-A, barely was undetectable in normal 
colon control cells whereas it was clearly expressed in tumoral cells (CD133+ and CD133-). 
Immunoblot analysis revealed a higher expression of Aurora-A in tumor specimen 
compared with normal tissue. Moreover, although in primary tumor cells immunoreactivity 
was cytoplasmic-located, the Aurora expression in CSC was also nuclear-located. The rare 
CD133+ cells presents in the normal colon population were mostly negative for Aurora-A 
expression. Eight of the 15 Aurora-A over expressing CSC cells lines were p53 wild type. 
Further investigation revealed that knockdown of Aurora-A in CSC resulted in significant 
growth inhibition, inhibition of migration in vitro, and in a limitation in their tumorigenic 
capacity on xenograft models with an increase in their susceptibility to chemotherapy 
induced death. 
5. Limits 
The experiments discussed above provide evidence that within a tumor, the high cell 
diversity is not result of a heterogeneous accumulation of diver mutations, but it is more 
probable that the diversity is the result of  a complex regulation program where only a 
subset of cells are responsible for tumor initiation and development. However, the isolation, 
characterization and the driving pathways of CSC’s are poorly understood and need to be 
further investigated.  
5.1 Stem cells and cancer stem cells 
The origin of CSC’s cells is thought to be from tissue stem cells. Thus it has been 
demonstrated that under specific conditions, it is possible to reprogram cells to have a stem-
like phenotype. Yu et al. demonstrated that the induction of expression of several gene 
expression (like Oct4, sox2, nanog, and LIN28 (Yu et al., 2007) or Oct3/4, sox2, Klf4, and c-
Myc) in human dermal fibroblasts can convert them into pluripotent cells with a phenotype 
virtually indistinguishable from embryonic stem cells. In another report, Takahashi et al. 
(Takahashi et al.) showed that expression of c-Myc can achieve the same result. The 
evidence that the proto-oncogene c-Myc may be part of the reprogramming of genes 
supports the hypothesis that under some conditions, it may be possible to reprogram a cell 
to have a stem-like phenotype. 
5.2 Stem cells identification 
As an example, while CD133 is supposedly one of the most efficient markers to identify 
CSC, its biological function on the cell remains unknown. In CRC cell lines (Caco-2 and 
LoVo) the knock-down for CD133 by siRNA resulted in a significant decrease in both the 
level of CD133 mRNA and protein expression without any evidence of impairing the cells in 
vitro rate of proliferation, migration or invasion. 
While widely utilized as a CSC marker, CD133 may not be the best marker due its 
expression as not being restricted to stem cells. Analysis of CD133 knockout mice revealed 
that this antigen is expressed in epithelial differentiated tissues of several adults’ organs 
including: parietal layer of the Bowman capsule, epithelium of proximal tubules, bile ducts, 
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and pancreatic duct (Shmelkov et al., 2008). On the colon of mice, CD133 was mostly 
expressed on the surface and the center of the intestinal crypt, which is typically composed 
of differentiated columnar absorptive cells.  
It has been shown that some tumors do not exhibit CD133+ cells (Dalerba et al., 2007, Ricci-
Vitiani et al., 2007, Ieta et al., 2008). In those cases, some of the CD133- cells have been 
reported as initiating cells with various and contradictory phenotypic profiles such as 
CD133-/CD44+/CD24- (Shmelkov et al., 2008) or CD133-/CD44-/CDX-2+/CK20+/CK7- 
(Navarro-Alvarez et al.). 
In addition to the characterization of a unique CSC profile, it is of critical importance to be 
able to discriminate the best sets of markers needed identify the CSC. Consequently to the 
genetic diversity of colon cancers, the CSC may also be varied among divers tumors but 
sharing similar phenotypic and function specificity.   
Different pathways implicated in CSC functions have been investigated. The hyper-
activation of pathways implicated in tumor proliferation and self-renewal has led to the 
development of several specifically targeted treatments to down regulate these pathways 
and improve the chemo sensitivity. Until now, these pathways are not specifically used by 
CSC and the efficiency and side effects when distributed throughout the whole body 
remains unknown. 
6. Conclusion 
In conclusion, research has demonstrated that with the heterogeneity of cells within a 
tumor, only a portion of these cells are tumorigenic. The characterization of these cells needs 
to be further investigated. The understanding of the implicated pathways will be critical for 
the development of new targeted therapies that are able to selectively treat the CSC 
population thereby to reduce a tumor’s ability to recur.  
7. References 
Anido, J., Saez-Borderias, A., Gonzalez-Junca, A., Rodon, L., Folch, G., Carmona, M.A., 
Prieto-Sanchez, R.M., Barba, I., Martinez-Saez, E., Prudkin, L., Cuartas, I., Raventos, 
C., Martinez-Ricarte, F., Poca, M.A., Garcia-Dorado, D., Lahn, M.M., Yingling, J.M., 
Rodon, J., Sahuquillo, J., Baselga, J. & Seoane, J. TGF-beta Receptor Inhibitors 
Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human 
Glioblastoma. Cancer Cell, Vol. 18, No. 6, pp. 655-68. 
Awad, O., Yustein, J.T., Shah, P., Gul, N., Katuri, V., O'Neill, A., Kong, Y., Brown, M.L., 
Toretsky, J.A. & Loeb, D.M. High ALDH activity identifies chemotherapy-resistant 
Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One, 
Vol. 5, No. 11, pp. e13943. 
Becker, L., Huang, Q. & Mashimo, H. (2008). Immunostaining of Lgr5, an intestinal stem cell 
marker, in normal and premalignant human gastrointestinal tissue. 
ScientificWorldJournal, Vol. 8, pp. 1168-76. 
Blazek, E.R., Foutch, J.L. & Maki, G. (2007). Daoy medulloblastoma cells that express CD133 
are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by 
hypoxia. Int J Radiat Oncol Biol Phys, Vol. 67, No. 1, pp. 1-5. 
Botchkina, G.I., Zuniga, E.S., Das, M., Wang, Y., Wang, H., Zhu, S., Savitt, A.G., Rowehl, 
R.A., Leyfman, Y., Ju, J., Shroyer, K. & Ojima, I. New-generation taxoid SB-T-1214 
www.intechopen.com
 
Cancer Stem Cells - The Cutting Edge 
 
162 
inhibits stem cell-related gene expression in 3D cancer spheroids induced by 
purified colon tumor-initiating cells. Mol Cancer, Vol. 9, pp. 192. 
Calcagno, A.M., Salcido, C.D., Gillet, J.P., Wu, C.P., Fostel, J.M., Mumau, M.D., Gottesman, 
M.M., Varticovski, L. & Ambudkar, S.V. Prolonged drug selection of breast cancer 
cells and enrichment of cancer stem cell characteristics. J Natl Cancer Inst, Vol. 102, 
No. 21, pp. 1637-52. 
Cammareri, P., Scopelliti, A., Todaro, M., Eterno, V., Francescangeli, F., Moyer, M.P., 
Agrusa, A., Dieli, F., Zeuner, A. & Stassi, G. Aurora-a is essential for the 
tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer 
Res, Vol. 70, No. 11, pp. 4655-65. 
Chang, C.J., Hsu, C.C., Yung, M.C., Chen, K.Y., Tzao, C., Wu, W.F., Chou, H.Y., Lee, Y.Y., 
Lu, K.H., Chiou, S.H. & Ma, H.I. (2009). Enhanced radiosensitivity and radiation-
induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 
expression. Biochem Biophys Res Commun, Vol. 380, No. 2, pp. 236-42. 
Croker, A.K., Goodale, D., Chu, J., Postenka, C., Hedley, B.D., Hess, D.A. & Allan, A.L. 
(2009). High aldehyde dehydrogenase and expression of cancer stem cell markers 
selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell 
Mol Med, Vol. 13, No. 8B, pp. 2236-52. 
Dalerba, P., Dylla, S.J., Park, I.K., Liu, R., Wang, X., Cho, R.W., Hoey, T., Gurney, A., Huang, 
E.H., Simeone, D.M., Shelton, A.A., Parmiani, G., Castelli, C. & Clarke, M.F. (2007). 
Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad 
Sci U S A, Vol. 104, No. 24, pp. 10158-63. 
Du, L., Wang, H., He, L., Zhang, J., Ni, B., Wang, X., Jin, H., Cahuzac, N., Mehrpour, M., Lu, 
Y. & Chen, Q. (2008). CD44 is of functional importance for colorectal cancer stem 
cells. Clin Cancer Res, Vol. 14, No. 21, pp. 6751-60. 
Ferrandina, G., Bonanno, G., Pierelli, L., Perillo, A., Procoli, A., Mariotti, A., Corallo, M., 
Martinelli, E., Rutella, S., Paglia, A., Zannoni, G., Mancuso, S. & Scambia, G. (2008). 
Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer, Vol. 18, 
No. 3, pp. 506-14. 
Florek, M., Haase, M., Marzesco, A.M., Freund, D., Ehninger, G., Huttner, W.B. & Corbeil, 
D. (2005). Prominin-1/CD133, a neural and hematopoietic stem cell marker, is 
expressed in adult human differentiated cells and certain types of kidney cancer. 
Cell Tissue Res, Vol. 319, No. 1, pp. 15-26. 
Gires, O., Klein, C.A. & Baeuerle, P.A. (2009). On the abundance of EpCAM on cancer stem 
cells. Nat Rev Cancer, Vol. 9, No. 2, pp. 143; author reply 143. 
Grimm, M., Kim, M., Rosenwald, A., Heemann, U., Germer, C.T., Waaga-Gasser, A.M. & 
Gasser, M. Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in 
colorectal cancer points to a specific role for inflammation-induced TLRs in 
tumourigenesis and tumour progression. Eur J Cancer, Vol. 46, No. 15, pp. 2849-57. 
Haraguchi, N., Ohkuma, M., Sakashita, H., Matsuzaki, S., Tanaka, F., Mimori, K., Kamohara, 
Y., Inoue, H. & Mori, M. (2008). CD133+CD44+ population efficiently enriches 
colon cancer initiating cells. Ann Surg Oncol, Vol. 15, No. 10, pp. 2927-33. 
Horst, D., Scheel, S.K., Liebmann, S., Neumann, J., Maatz, S., Kirchner, T. & Jung, A. (2009). 
The cancer stem cell marker CD133 has high prognostic impact but unknown 
functional relevance for the metastasis of human colon cancer. J Pathol, Vol. 219, 
No. 4, pp. 427-34. 
www.intechopen.com
 
What do We Know About Cancer Stem Cells? Utilizing Colon Cancer as an Example   
 
163 
Huang, E.H., Hynes, M.J., Zhang, T., Ginestier, C., Dontu, G., Appelman, H., Fields, J.Z., 
Wicha, M.S. & Boman, B.M. (2009). Aldehyde dehydrogenase 1 is a marker for 
normal and malignant human colonic stem cells (SC) and tracks SC overpopulation 
during colon tumorigenesis. Cancer Res, Vol. 69, No. 8, pp. 3382-9. 
Huang, M., Li, Y., Zhang, H. & Nan, F. Breast cancer stromal fibroblasts promote the 
generation of CD44+CD24- cells through SDF-1/CXCR4 interaction. J Exp Clin 
Cancer Res, Vol. 29, pp. 80. 
Ieta, K., Tanaka, F., Haraguchi, N., Kita, Y., Sakashita, H., Mimori, K., Matsumoto, T., Inoue, 
H., Kuwano, H. & Mori, M. (2008). Biological and genetic characteristics of tumor-
initiating cells in colon cancer. Ann Surg Oncol, Vol. 15, No. 2, pp. 638-48. 
Joshua, B., Kaplan, M.J., Doweck, I., Pai, R., Weissman, I.L., Prince, M.E. & Ailles, L.E. 
Frequency of cells expressing CD44, a Head and Neck cancer stem cell marker: 
Correlation with tumor aggressiveness. Head Neck. 
Kim, Y.M., Ma, H., Oehler, V.G., Gang, E.J., Nguyen, C., Masiello, D., Liu, H., Zhao, Y., 
Radich, J. & Kahn, M. The gamma catenin/CBP complex maintains survivin 
transcription in beta-catenin deficient/depleted cancer cells. Curr Cancer Drug 
Targets, Vol. 11, No. 2, pp. 213-25. 
Kusumbe, A.P. & Bapat, S.A. (2009). Cancer stem cells and aneuploid populations within 
developing tumors are the major determinants of tumor dormancy. Cancer Res, Vol. 
69, No. 24, pp. 9245-53. 
Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.B., Lecomte, T., Rougier, P., 
Lievre, A., Landi, B., Boige, V., Ducreux, M., Ychou, M., Bibeau, F., Bouche, O., 
Reid, J., Stone, S. & Penault-Llorca, F. (2009). Analysis of PTEN, BRAF, and EGFR 
status in determining benefit from cetuximab therapy in wild-type KRAS 
metastatic colon cancer. J Clin Oncol, Vol. 27, No. 35, pp. 5924-30. 
Leung, E.L., Fiscus, R.R., Tung, J.W., Tin, V.P., Cheng, L.C., Sihoe, A.D., Fink, L.M., Ma, Y. & 
Wong, M.P. Non-small cell lung cancer cells expressing CD44 are enriched for stem 
cell-like properties. PLoS One, Vol. 5, No. 11, pp. e14062. 
Ma, H., Nguyen, C., Lee, K.S. & Kahn, M. (2005). Differential roles for the coactivators CBP 
and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene, Vol. 
24, No. 22, pp. 3619-31. 
Moriyama, T., Ohuchida, K., Mizumoto, K., Cui, L., Ikenaga, N., Sato, N. & Tanaka, M. 
Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured 
with pancreatic stromal cells. Cancer, Vol. 116, No. 14, pp. 3357-68. 
Munz, M., Baeuerle, P.A. & Gires, O. (2009). The emerging role of EpCAM in cancer and 
stem cell signaling. Cancer Res, Vol. 69, No. 14, pp. 5627-9. 
Murphy (1914). Heteroplastic tissue grafting effected though roentgen-ray lymphoid 
destruction. J. Am. Med. Assoc., Vol. 62, pp. 1459. 
Navarro-Alvarez, N., Kondo, E., Kawamoto, H., Hassan, W., Yuasa, T., Kubota, Y., Seita, M., 
Nakahara, H., Hayashi, T., Nishikawa, Y., Hassan, R.A., Javed, S.M., Noguchi, H., 
Matsumoto, S., Nakaji, S., Tanaka, N., Kobayashi, N. & Soto-Gutierrez, A. Isolation 
and propagation of a human CD133(-) colon tumor-derived cell line with 
tumorigenic and angiogenic properties. Cell Transplant, Vol. 19, No. 6, pp. 865-77. 
O'Brien, C.A., Pollett, A., Gallinger, S. & Dick, J.E. (2007). A human colon cancer cell capable 
of initiating tumour growth in immunodeficient mice. Nature, Vol. 445, No. 7123, 
pp. 106-10. 
www.intechopen.com
 
Cancer Stem Cells - The Cutting Edge 
 
164 
Pajonk, F., Vlashi, E. & McBride, W.H. Radiation resistance of cancer stem cells: the 4 R's of 
radiobiology revisited. Stem Cells, Vol. 28, No. 4, pp. 639-48. 
Phillips, T.M., McBride, W.H. & Pajonk, F. (2006). The response of CD24(-/low)/CD44+ 
breast cancer-initiating cells to radiation. J Natl Cancer Inst, Vol. 98, No. 24, pp. 
1777-85. 
Ponti, D., Zaffaroni, N., Capelli, C. & Daidone, M.G. (2006). Breast cancer stem cells: an 
overview. Eur J Cancer, Vol. 42, No. 9, pp. 1219-24. 
Rasheed, Z., Wang, Q. & Matsui, W. Isolation of stem cells from human pancreatic cancer 
xenografts. J Vis Exp, No. 43. 
Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C. & De Maria, 
R. (2007). Identification and expansion of human colon-cancer-initiating cells. 
Nature, Vol. 445, No. 7123, pp. 111-5. 
Ricci-Vitiani, L., Mollinari, C., di Martino, S., Biffoni, M., Pilozzi, E., Pagliuca, A., de Stefano, 
M.C., Circo, R., Merlo, D., De Maria, R. & Garaci, E. Thymosin beta4 targeting 
impairs tumorigenic activity of colon cancer stem cells. FASEB J, Vol. 24, No. 11, pp. 
4291-301. 
Richardson, G.D., Robson, C.N., Lang, S.H., Neal, D.E., Maitland, N.J. & Collins, A.T. (2004). 
CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci, Vol. 117, 
No. Pt 16, pp. 3539-45. 
Rowehl, R.A., Crawford, H., Dufour, A., Ju, J. & Botchkina, G.I. (2008). Genomic analysis of 
prostate cancer stem cells isolated from a highly metastatic cell line. Cancer 
Genomics Proteomics, Vol. 5, No. 6, pp. 301-10. 
Saigusa, S., Tanaka, K., Toiyama, Y., Yokoe, T., Okugawa, Y., Kawamoto, A., Yasuda, H., 
Morimoto, Y., Fujikawa, H., Inoue, Y., Miki, C. & Kusunoki, M. 
Immunohistochemical features of CD133 expression: association with resistance to 
chemoradiotherapy in rectal cancer. Oncol Rep, Vol. 24, No. 2, pp. 345-50. 
Shi, C., Tian, R., Wang, M., Wang, X., Jiang, J., Zhang, Z., Li, X., He, Z., Gong, W. & Qin, R. 
CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human 
gallbladder carcinoma. Cancer Biol Ther, Vol. 10, No. 11, pp. 1182-90. 
Shmelkov, S.V., Butler, J.M., Hooper, A.T., Hormigo, A., Kushner, J., Milde, T., St Clair, R., 
Baljevic, M., White, I., Jin, D.K., Chadburn, A., Murphy, A.J., Valenzuela, D.M., 
Gale, N.W., Thurston, G., Yancopoulos, G.D., D'Angelica, M., Kemeny, N., Lyden, 
D. & Rafii, S. (2008). CD133 expression is not restricted to stem cells, and both 
CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest, Vol. 
118, No. 6, pp. 2111-20. 
Sikandar, S.S., Pate, K.T., Anderson, S., Dizon, D., Edwards, R.A., Waterman, M.L. & Lipkin, 
S.M. NOTCH signaling is required for formation and self-renewal of tumor-
initiating cells and for repression of secretory cell differentiation in colon cancer. 
Cancer Res, Vol. 70, No. 4, pp. 1469-78. 
Song, B., Wang, Y., Xi, Y., Kudo, K., Bruheim, S., Botchkina, G.I., Gavin, E., Wan, Y., 
Formentini, A., Kornmann, M., Fodstad, O. & Ju, J. (2009). Mechanism of 
chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer 
cells. Oncogene, Vol. 28, No. 46, pp. 4065-74. 
Stoecklein, N.H., Siegmund, A., Scheunemann, P., Luebke, A.M., Erbersdobler, A., Verde, 
P.E., Eisenberger, C.F., Peiper, M., Rehders, A., Esch, J.S., Knoefel, W.T. & Hosch, 
S.B. (2006). Ep-CAM expression in squamous cell carcinoma of the esophagus: a 
potential therapeutic target and prognostic marker. BMC Cancer, Vol. 6, pp. 165. 
www.intechopen.com
 
What do We Know About Cancer Stem Cells? Utilizing Colon Cancer as an Example   
 
165 
Sullivan, J.P., Spinola, M., Dodge, M., Raso, M.G., Behrens, C., Gao, B., Schuster, K., Shao, C., 
Larsen, J.E., Sullivan, L.A., Honorio, S., Xie, Y., Scaglioni, P.P., DiMaio, J.M., 
Gazdar, A.F., Shay, J.W., Wistuba, II & Minna, J.D. Aldehyde dehydrogenase 
activity selects for lung adenocarcinoma stem cells dependent on notch signaling. 
Cancer Res, Vol. 70, No. 23, pp. 9937-48. 
Takahashi-Yanaga, F. & Kahn, M. Targeting Wnt signaling: can we safely eradicate cancer 
stem cells? Clin Cancer Res, Vol. 16, No. 12, pp. 3153-62. 
Takahashi, H., Ishii, H., Nishida, N., Takemasa, I., Mizushima, T., Ikeda, M., Yokobori, T., 
Mimori, K., Yamamoto, H., Sekimoto, M., Doki, Y. & Mori, M. Significance of 
Lgr5(+ve) Cancer Stem Cells in the Colon and Rectum. Ann Surg Oncol. 
Takaishi, S., Okumura, T., Tu, S., Wang, S.S., Shibata, W., Vigneshwaran, R., Gordon, S.A., 
Shimada, Y. & Wang, T.C. (2009). Identification of gastric cancer stem cells using 
the cell surface marker CD44. Stem Cells, Vol. 27, No. 5, pp. 1006-20. 
Takeda, K., Kinoshita, I., Shimizu, Y., Matsuno, Y., Shichinohe, T. & Dosaka-Akita, H. 
Expression of LGR5, an intestinal stem cell marker, during each stage of colorectal 
tumorigenesis. Anticancer Res, Vol. 31, No. 1, pp. 263-70. 
Tan, S., Chen, J.S., Sun, L.J. & Yao, H.R. (2009). Selective enrichment of hepatocellular cancer 
stem cells by chemotherapy. J Int Med Res, Vol. 37, No. 4, pp. 1046-56. 
Todaro, M., Alea, M.P., Di Stefano, A.B., Cammareri, P., Vermeulen, L., Iovino, F., Tripodo, 
C., Russo, A., Gulotta, G., Medema, J.P. & Stassi, G. (2007). Colon cancer stem cells 
dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem 
Cell, Vol. 1, No. 4, pp. 389-402. 
Tomuleasa, C., Soritau, O., Rus-Ciuca, D., Pop, T., Todea, D., Mosteanu, O., Pintea, B., Foris, 
V., Susman, S., Kacso, G. & Irimie, A. Isolation and characterization of hepatic 
cancer cells with stem-like properties from hepatocellular carcinoma. J 
Gastrointestin Liver Dis, Vol. 19, No. 1, pp. 61-7. 
Varnat, F., Duquet, A., Malerba, M., Zbinden, M., Mas, C., Gervaz, P. & Ruiz i Altaba, A. 
(2009). Human colon cancer epithelial cells harbour active HEDGEHOG-GLI 
signalling that is essential for tumour growth, recurrence, metastasis and stem cell 
survival and expansion. EMBO Mol Med, Vol. 1, No. 6-7, pp. 338-51. 
Vermeulen, L., De Sousa, E.M.F., van der Heijden, M., Cameron, K., de Jong, J.H., Borovski, 
T., Tuynman, J.B., Todaro, M., Merz, C., Rodermond, H., Sprick, M.R., Kemper, K., 
Richel, D.J., Stassi, G. & Medema, J.P. Wnt activity defines colon cancer stem cells 
and is regulated by the microenvironment. Nat Cell Biol, Vol. 12, No. 5, pp. 468-76. 
Vermeulen, L., Todaro, M., de Sousa Mello, F., Sprick, M.R., Kemper, K., Perez Alea, M., 
Richel, D.J., Stassi, G. & Medema, J.P. (2008). Single-cell cloning of colon cancer 
stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A, 
Vol. 105, No. 36, pp. 13427-32. 
Wang, J.C. & Dick, J.E. (2005). Cancer stem cells: lessons from leukemia. Trends Cell Biol, Vol. 
15, No. 9, pp. 494-501. 
Wang, J.Y., Wu, C.H., Lu, C.Y., Hsieh, J.S., Wu, D.C., Huang, S.Y. & Lin, S.R. (2006). 
Molecular detection of circulating tumor cells in the peripheral blood of patients 
with colorectal cancer using RT-PCR: significance of the prediction of postoperative 
metastasis. World J Surg, Vol. 30, No. 6, pp. 1007-13. 
Wang, W.S., Chen, P.M., Hsiao, H.L., Wang, H.S., Liang, W.Y. & Su, Y. (2004). 
Overexpression of the thymosin beta-4 gene is associated with increased invasion 
www.intechopen.com
 
Cancer Stem Cells - The Cutting Edge 
 
166 
of SW480 colon carcinoma cells and the distant metastasis of human colorectal 
carcinoma. Oncogene, Vol. 23, No. 39, pp. 6666-71. 
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., 
Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, II & Thomson, J.A. (2007). Induced 
pluripotent stem cell lines derived from human somatic cells. Science, Vol. 318, No. 
5858, pp. 1917-20. 
Zhang, H.Z., Wei, Y.P., Wang, M., Wu, C., Yang, Y.Q., Chen, J. & Cao, Y.K. (2007). 
[Association of CD133 and endothelin-converting enzyme expressions with 
prognosis of non-small cell lung carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao, Vol. 
27, No. 5, pp. 696-9. 
Zhu, L., Gibson, P., Currle, D.S., Tong, Y., Richardson, R.J., Bayazitov, I.T., Poppleton, H., 
Zakharenko, S., Ellison, D.W. & Gilbertson, R.J. (2009). Prominin 1 marks intestinal 
stem cells that are susceptible to neoplastic transformation. Nature, Vol. 457, No. 
7229, pp. 603-7. 
 
 
 
 
 
www.intechopen.com
Cancer Stem Cells - The Cutting Edge
Edited by Prof. Stanley Shostak
ISBN 978-953-307-580-8
Hard cover, 606 pages
Publisher InTech
Published online 01, August, 2011
Published in print edition August, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Over the last thirty years, the foremost inspiration for research on metastasis, cancer recurrence, and
increased resistance to chemo- and radiotherapy has been the notion of cancer stem cells.The twenty-eight
chapters assembled in Cancer Stem Cells - The Cutting Edge summarize the work of cancer researchers and
oncologists at leading universities and hospitals around the world on every aspect of cancer stem cells, from
theory and models to specific applications (glioma), from laboratory research on signal pathways to clinical
trials of bio-therapies using a host of devices, from solutions to laboratory problems to speculation on
cancersâ€™ stem cellsâ€™ evolution. Cancer stem cells may or may not be a subset of slowly dividing cancer
cells that both disseminate cancers and defy oncotoxic drugs and radiation directed at rapidly dividing bulk
cancer cells, but research on cancer stem cells has paid dividends for cancer prevention, detection, targeted
treatment, and improved prognosis.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Benhaim Leonor, Labonte Melissa and Lenz Heinz-Joseph (2011). What do We Know About Cancer Stem
Cells? Utilizing Colon Cancer as an Example, Cancer Stem Cells - The Cutting Edge, Prof. Stanley Shostak
(Ed.), ISBN: 978-953-307-580-8, InTech, Available from: http://www.intechopen.com/books/cancer-stem-cells-
the-cutting-edge/what-do-we-know-about-cancer-stem-cells-utilizing-colon-cancer-as-an-example
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
